Superficial Vein Thrombosis: Gregory Piazza Leads JAMA Review Addressing An Underrecognized Challenge
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, posted on LinkedIn:
”Superficial vein thrombosis is a challenging venous thromboembolic disorder because of the paucity of randomized controlled trial data and limited guidance in the literature. Despite this, the patient burden is high. Accordingly, clinicians are often left to “fend for themselves”. Very proud of this review in JAMA from my research team that gives clinicians and patients some pathways forward. Our research fellow and a first year medical student at Tufts, Darsiya Krishnathasan, started this as her undergraduate thesis. An incredible effort with amazing guidance from my colleague, Dr. Behnood Bikdeli. ”
Read the full review here.
Title: Superficial Vein Thrombosis: A Review
Authors: Gregory Piazza, Darsiya Krishnathasan, Nada Hamade, Francisco Ujueta, Giovanni Scimeca, Marcos D. Ortiz-Rios, Bridget McGonagle, Jean-Philippe Galanaud, David Jiménez, Manuel Monreal, John Fanikos, Anahita Dua, Leben Tefera, Raghu Kolluri, Sahil A. Parikh, Walter Ageno, Samuel Z. Goldhaber, Jeffrey I. Weitz, Lisa K. Moores, Isabelle Quéré, Behnood Bikdeli
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia